Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy ...
Selling beyond theme parksWith record demand for theme parks starting to cool, advisors would do well to diversify. Fall brings a feast of festivals in HawaiiFrom cowboys to coffee, cultural and ...